Citadel Advisors
RPRX

Citadel Advisors’s Repros Therapeutics Inc. RPRX Stock Holding History

Citadel Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,800
Closed -$7K – 9366
2015
Q4 		$7K Sell
5,800
-900
-13% -$2.89K ﹤0.01% 8401
2015
Q3 		$50K Buy
6,700
+5,300
+379% +$40.5K ﹤0.01% 7593
2015
Q2 		$10K Sell
1,400
-5,400
-79% -$42.1K ﹤0.01% 8426
2015
Q1 		$58K Sell
6,800
-25,400
-79% -$227K ﹤0.01% 7293
2014
Q4 		$321K Buy
32,200
+3,300
+11% +$28.1K ﹤0.01% 5335
2014
Q3 		$286K Buy
28,900
+2,900
+11% +$42.9K ﹤0.01% 5322
2014
Q2 		$450K Sell
26,000
-6,600
-20% -$108K ﹤0.01% 4541
2014
Q1 		$578K Sell
32,600
-9,700
-23% -$188K ﹤0.01% 4146
2013
Q4 		$774K Sell
42,300
-23,100
-35% -$436K ﹤0.01% 3498
2013
Q3 		$1.75M Sell
65,400
-12,200
-16% -$261K ﹤0.01% 2542
2013
Q2 		$1.43M Buy
+77,600
New +$1.37M ﹤0.01% 2812

Citadel Advisors's RPRX Position: Q1 2018 in Review

Citadel Advisors sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 15,518 shares — an estimated $10K sold.

Citadel Advisors first reported a position in RPRX in Q2 2013 and held it in 11 quarters. The position peaked at $35.8M in Q3 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.

  • Citadel Advisors reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
  • Citadel Advisors sold 15,518 Repros Therapeutics Inc. shares in Q1 2018, an estimated $10K.
  • Citadel Advisors first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 11 quarters.
  • Citadel Advisors's Repros Therapeutics Inc. position peaked at $35.8M in Q3 2013.
  • 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.

Based on Citadel Advisors's 13F filing for Q1 2018, filed 11 May 2018.